EXAS | Exact Sciences Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	56.94 - 59.95
52 Week Range	40.62 - 79.62
Beta	1.28
Implied Volatility	73.10%
IV Rank	58.33%
Day's Volume	2,198,997
Average Volume	2,334,816
Shares Outstanding	185,076,000
Market Cap	10,567,839,600
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2001-02-01

Valuation
Profitability
Growth
Health
P/E Ratio	-49.22
Forward P/E Ratio	-31.18
EPS	-1.16
1YR Price Target	86.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6,500
Country	USA
Website	EXAS

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.

EXAS's peers: CDNA, NTRA, ILMN, TWST, A, TMO, NVTA, DHR, GH, CRL, MYGN, CSTL, FLGT

*Chart delayed

Analyzing fundamentals for EXAS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see EXAS Fundamentals page.

Watching at EXAS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EXAS Technicals page.